Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

July 30, 2018 6:16 PM UTC

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX).

Glycotope will receive an undisclosed upfront payment and is eligible for development and sales milestones, plus royalties. Daiichi gained the option to license gatipotuzumab in 2017. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Target Profiles

Mucin 1 (MUC1) (CD227)